Elsevier

Medical Hypotheses

Volume 74, Issue 1, January 2010, Pages 7-11
Medical Hypotheses

Similarities in features of autism and asthma and a possible link to acetaminophen use

https://doi.org/10.1016/j.mehy.2009.08.033Get rights and content

Summary

Autism and autism spectrum disorders are enigmatic conditions that have their origins in the interaction of genes and environmental factors. In this hypothesis, genes statistically associated with autism are emphasized to be important in inflammation and in innate immune pathways, including pathways for susceptibility to asthma. The role of acetaminophen (paracetamol) in an increased risk for asthma is described and a possible similar link to an increased risk for autism is suggested.

Introduction

Autism is a complex and heterogeneous disorder, and the etiology is unknown. Although numerous theories of early initiating events in the development of autism have been proposed, two areas of active scientific interest are immune dysregulation and genetic predisposition. In this report we compare immune and genetic aspects of autism. We then describe acetaminophen’s link to asthma and suggest a link with acetaminophen to immune anomalies in autism.

There are an increasing number of reports that anomalies in the immune system may play a role in autism. This has been found at the molecular, pathological, and epidemiological level. Altered levels of immunoglobulins [1], [2], [3], cytokines [4] and, inflammatory markers have been identified in the serum [5], cerebral spinal fluid [6], and autopsy brain tissues [2] of autistic patients. Gastrointestinal inflammation in autism [7] as well as pathological evidence of neuroinflammation involving activation of brain microglia has been shown [8]. An increase in head circumference in autistic children [9], a consistent finding in autism, may involve neuroinflammation. Abnormalities in macrophages [8], [10] and mast cells in autism have also been noted [11]. Differential monocyte responses to Toll-like receptors have been found in children with autism spectrum disorders suggesting involvement of innate immune pathways [12]. Interestingly, activation of TLR2 has been shown to inhibit embryonic neural progenitor cell proliferation resulting in cortical dysgenesis in vitro and in utero in a mouse model (unpublished).

In addition, epidemiological evidence of immune involvement has been shown through an increased frequency of autoimmune disorders in family members of autistic patients [13], [14], [15]. Comparisons to early events between childhood asthma and autism have been suggested, including an increase in head circumference and male preponderance, among others [16]. There is no evidence of T cell mediated autoimmune tissue destruction as found in classical autoimmune disorders. Immune involvement in autism has recently been reviewed [17], [18], [19]. Interestingly, alterations in fever have been hypothesized to be involved in the etiology of autism [20] and fever has recently been shown to transiently improve both behavior and language in autistic patients [21]. Also, low levels of breastfeeding could decrease immune protection in infants by decreasing mother to child transfer of IgA. Breastfeeding has been linked to autism risk in the authors’ previous work [22].

Although autism has been shown to be highly heritable, the genetic underpinnings of autism are complex and unclear [23]. The relationship of genetic findings to the etiology, pathobiology, disease incidence in the population, or clinical course of the disease is obscure and speculative. While several important genes identified in genetic association studies in autism are often discussed in the context of synaptogenesis and brain development, a number of these autism candidate genes are central to the genetics or immunobiology of inflammatory disorders, including asthma and macrophage or mast cell dysfunction [23], [24]. These genes include PTEN, MET, SERPINE1, PLAUR, ITGB3, ADRB2, and MIF.

PTEN, phosphatase and tensin homolog, is an important regulatory checkpoint in the inhibition of the PI3 K/Akt/mTOR pathway [24] which is central to innate immunity as well as mast cell [25] and macrophage biology [26]. PTEN has been associated with autism spectrum disorders and macrocephaly [27] and autism related phenotypes in a mouse model [28].

MET, the met proto-oncogene also known as hepatocyte growth factor receptor, has been associated with autism in multiple studies [29], [30]. MET has also been shown to be a regulator of mast cell activation as a co-receptor with α2β1 integrin [31]. In addition, both SERPINE1 and PLAUR, two genes involved in the MET signaling cascade and in the fibrinolytic system, have both been genetically associated with autism [32] and asthma [33]. Both PLAUR (uPAR) and SERPINE1 (PAI-1) have been shown to be highly expressed in macrophages, activated brain microglia [34], as well as in mast cells [35]. Both PLAUR and SERPINE1 may play an important role in the pathogenesis of asthma [36], [37].

Integrin beta 3 (ITGB3) on chromosome 17 codes for a cell-surface molecule involved in cell-surface mediated signaling and cell adhesion. Polymorphisms in ITGB3 have been associated with multiple disorders including autism [38] and asthma [33], [39] in genetic association studies. ITGB3 (CD61) is found on the surface of mast cells where it is involved in binding vitronectin and mast cell activation [40], [41] and cell signaling in macrophages.[42]

ADRB2, the beta-2 adrenergic receptor, is a G protein-coupled receptor that is expressed ubiquitously and influences many pathological states including asthma, obesity and Type 2 diabetes. The Glu27 allele of ADRB2 been associated with autism [43] in the AGRE [44] cohort as well as in dizygotic twins [45]. This polymorphism of ADRB2 is also associated with asthma disease severity and drug response [46].

MIF, or macrophage migration inhibitory factor, codes for a cytokine involved in immunoregulation and inflammation [47] in T lymphocytes, pituitary cells, astrocytes, macrophages, smooth muscles cells, endothelial cells, and mast cells [48]. Polymorphisms in the promoter of MIF have recently been associated with autism spectrum disorders [49], as well as in allergic asthma [50], and have been shown to be required for allergic inflammation in a mouse model of asthma [50]. In addition, polymorphisms in MIF have been associated with Hereditary Periodic Fever (HPF) syndromes as well as regulating serum MIF concentrations [51]. Interestingly, in all three cases, autism, asthma, and HPF, the – 173G/C promoter polymorphism which alters levels of MIF gene transcription was an associated allele. Importantly, the metabolite of acetaminophen, N-acetyl-p-benzoquinone imine (NAPQI), inhibits the isomerase and the biological activities of MIF [52].

The genes described above having been commonly identified in autism, asthma, and inflammation suggests an overlap in genetic susceptibility factors between these disorders. This raises the possibility that environmental factors acting through gene-environment interactions may act in similar ways in both disorders.

Acetaminophen (paracetamol) is a widely used over-the-counter pain reliever and fever reducer (antipyretic) that was introduced in the US in 1955 [22]. Acetaminophen largely replaced aspirin for the treatment of pediatric fever after the CDC advisory in 1980 to physicians and parents regarding an association between aspirin and Reye’s syndrome. Acetaminophen overdose is a leading cause of hepatotoxicity and acute liver failure. Activation of liver Kupfer cells (phagocytic macrophages of the liver) by acetaminophen metabolites have been shown to activate cytokines and alter innate immunity in liver injury [53]. Acetaminophen has been suggested to alter the Th1/Th2 cytokine balance in acetaminophen induced liver injury [54] and to act through TLR4 [55] and TLR9 [56]. In addition, acetaminophen has recently been shown to alter protein levels and phosphorylation of PTEN and S-nitrosylated Akt in a chronic rat model of muscle aging [57].

Most importantly, acetaminophen use in the first year of life has been strongly associated with a later increased risk of asthma, and related phenotypes of asthma [58]. This association was recently found to have a dose dependent risk of childhood asthma, rhinoconjuctivitis, and ezcema in children aged 6–7 years, in a large multinational study [59]. Moreover, increased risk of asthma due to acetaminophen use in late pregnancy has also been shown [60]. The exact molecular mechanism of this increased risk of asthma and allergic disorders due to acetaminophen use is not known [61], although mechanistic theories include alterations in glutathione levels, effects on serotonin, suppression of COX2, and specific effects of acetaminophen breakdown products [62] such as NAPQI. Importantly, acetaminophen use after MMR vaccination has recently been associated with autism in a small case controlled study [63], this association was not seen with ibuprofen.

Moreover, acetaminophen affects glutathione levels as well as pathways involved in transsulfuration. Glutathione metabolism is fundamental to many biological processes and alterations in glutathione homeostasis are implicated in numerous human diseases including immune and inflammatory disorders [64]. Polymorphisms in glutathione pathways have been associated with both autism and inflammatory disorders [64], [65], [66], [67]. Glutathione reductase has been shown to be inhibited through acetaminophen–glutathione conjugates [68]. The transsulfuration pathway converts cysteine to homocysteine through the intermediate cystathione. Transsulfation metabolism has been shown to be altered in children with autism [69] and parents of children with autism [70].

Numerous studies have attempted to measure the prevalence of autism and asthma in the population [71], [72], [73]. Both asthma and autism have had a similar apparent rise in the number of cases since approximately 1980, over the past 30 years, and in both disorders these have been repeatedly referred to as “epidemics”. In autism, this apparent rise in cases is highly controversial [74] and may be whole or in part due to increased disease awareness and/or expansion and reclassification of diagnostic criteria.

The following discussion is not intended to judge the validity of disease prevalence studies in asthma or autism; it is simply to point out interesting minor anomalies in those curves. In disease prevalence curves of both autism and asthma in the US, the sharp rise in cases began in approximately 1980. In the period from 1980 to 1990 there were two slight downturns in the slope of the curves, after 1982 and after 1986. Both curves continue markedly upward after 1988 into the 1990s (see Fig. 1 and (Fig. 2).). In addition, there are similar slight downturns in slopes of the curves at the same times from independent and geographically disparate studies in both asthma and autism including; asthma hospitalizations [75], autism cases in Minnesota [76], autism in north east London [77], and autism in an urban area in Sweden [78] (see supplementary Figs. S1–S4).

Four significant events related to acetaminophen use occurred between 1980 and 1990. The first was the CDC caution in 1980 concerning the relationship of aspirin to the risk of Reyes Syndrome which was followed by a public and professional warning by the United States Surgeon General regarding a possible Reyes Syndrome–aspirin association [79]. These cautions against the use of aspirin as a fever reducer in children were largely responsible for the replacement of aspirin by acetaminophen as a pediatric antipyretic [80].

In 1982 and again in 1986 there were product tampering cases where acetaminophen tablets were laced with cyanide resulting in eight deaths. Acetaminophen sales collapsed after each tampering event, but recovered in less than a year in each case [81], [82], [83]. These dates roughly correspond to the slight downturns in asthma and autism cases mentioned above.

Section snippets

Hypothesis

The discussion above provides multiple lines of evidence for overlap in genetic susceptibility, molecular pathways, and other features associated with early preclinical etiological events in autism and asthma. A number of these features including biological, genetic, and epidemiological evidence may converge in aspects of inflammation or innate immunity, often involving macrophages or mast cells.

There is strong epidemiological evidence that acetaminophen use in late pregnancy and/or in the

Limitations

No evidence is presented here that acetaminophen in any way causes autism. Readers of this hypothesis should not conclude that acetaminophen is central to the etiology of autism or speculate beyond what is presented here. This hypothesis is largely based on multiple lines of often weak evidence. It is hoped that further research can clearly strengthen or disprove the ideas presented here.

Conflict of interest statement

None declared.

Acknowledgements

This research was supported by the Intramural Research Program of the NIH, National Institute on Aging, National Institutes of Health. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the United States Government.

References (84)

  • K.D. McCall-Culbreath et al.

    Crosstalk between the alpha2beta1 integrin and c-met/HGF-R regulates innate immunity

    Blood

    (2008)
  • C. Sillaber et al.

    Molecular and functional characterization of the urokinase receptor on human mast cells

    J Biol Chem

    (1997)
  • E.E. Thompson et al.

    Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life

    J Allergy Clin Immunol

    (2007)
  • M. Columbo et al.

    Human skin mast cells adhere to vitronectin via the alphavbeta3 integrin receptor (CD51/CD61)

    J Allergy Clin Immunol

    (2001)
  • Z. Jakus et al.

    Immunoreceptor-like signaling by beta 2 and beta 3 integrins

    Trends Cell Biol

    (2007)
  • D.H. Geschwind et al.

    The autism genetic resource exchange: a resource for the study of autism and related neuropsychiatric conditions

    Am J Hum Genet

    (2001)
  • Y. Masubuchi et al.

    Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury

    Chem Biol Interact

    (2009)
  • R. Beasley et al.

    Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from phase three of the ISAAC programme

    Lancet

    (2008)
  • I. Eneli et al.

    Acetaminophen and the risk of asthma: the epidemiologic and pathophysiologic evidence

    Chest

    (2005)
  • B. Taylor et al.

    Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association

    Lancet

    (1999)
  • L. Heuer et al.

    Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms

    Autism Res

    (2008)
  • D.L. Vargas et al.

    Neuroglial activation and neuroinflammation in the brain of patients with autism

    Ann Neurol

    (2005)
  • L.M. Elder et al.

    Head circumference as an early predictor of autism symptoms in younger siblings of children with autism spectrum disorder

    J Autism Dev Disord

    (2008)
  • A. Weizman et al.

    Abnormal immune response to brain tissue antigen in the syndrome of autism

    Am J Psychiatry

    (1982)
  • T.C. Theoharides et al.

    Autism, gut–blood–brain barrier, and mast cells

    J Clin Psychopharmacol

    (2008)
  • A.M. Enstrom et al.

    Differential monocyte responses to TLR ligands in children with autism spectrum disorders

    Brain Behav Immun

    (2009)
  • A.M. Comi et al.

    Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism

    J Child Neurol

    (1999)
  • C.A. Molloy et al.

    Familial autoimmune thyroid disease as a risk factor for regression in children with autism spectrum disorder: a CPEA study

    J Autism Dev Disord

    (2006)
  • H.O. Atladottir et al.

    Association of family history of autoimmune diseases and autism spectrum disorders

    Pediatrics

    (2009)
  • A.M. Enstrom et al.

    Autoimmunity in autism

    Curr Opin Invest Drugs

    (2009)
  • M.L. Castellani et al.

    Autism and immunity: revisited study

    Int J Immunopathol Pharmacol

    (2009)
  • P. Ashwood et al.

    The immune response in autism: a new frontier for autism research

    J Leukoc Biol

    (2006)
  • A.R. Torres

    Is fever suppression involved in the etiology of autism and neurodevelopmental disorders?

    BMC Pediatr

    (2003)
  • L.K. Curran et al.

    Behaviors associated with fever in children with autism spectrum disorders

    Pediatrics

    (2007)
  • S. Schultz

    Autism risk

    (2008)
  • S.E. Folstein et al.

    Genetics of autism: complex aetiology for a heterogeneous disorder

    Nat Rev Genet

    (2001)
  • A.W. Thomson et al.

    Immunoregulatory functions of mTOR inhibition

    Nat Rev Immunol

    (2009)
  • D.T. Page et al.

    Haploinsufficiency for PTEN and serotonin transporter cooperatively influences brain size and social behavior

    Proc Natl Acad Sci USA

    (2009)
  • D.B. Campbell et al.

    A genetic variant that disrupts MET transcription is associated with autism

    Proc Natl Acad Sci USA

    (2006)
  • I. Sousa et al.

    MET and autism susceptibility: family and case-control studies

    Eur J Hum Genet

    (2009)
  • D.B. Campbell et al.

    Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder

    Autism Res

    (2008)
  • A.J. Rogers et al.

    Assessing the reproducibility of asthma candidate gene associations, using genome-wide data

    Am J Respir Crit Care Med

    (2009)
  • Cited by (52)

    • Prenatal paracetamol exposure and child neurodevelopment: A review

      2018, Hormones and Behavior
      Citation Excerpt :

      He proposed that antipyretics might interfere with normal immunological development in the brain leading to neurodevelopmental disorders, such as ASD, in those genetically and immunologically predisposed. This hypothesis was followed by two supportive ecological analyses (Becker and Schultz, 2010; Bauer and Kriebel, 2013), but this question has only recently been investigated in well-conducted studies. The purpose of this review is to summarize and assess the findings of observational studies evaluating the association between prenatal exposure to APAP and offspring adverse neurodevelopmental outcomes and to provide an overview of plausible biological mechanisms for such a relationship.

    • Developmental neurotoxicity of inhaled ambient ultrafine particle air pollution: Parallels with neuropathological and behavioral features of autism and other neurodevelopmental disorders

      2017, NeuroToxicology
      Citation Excerpt :

      Perhaps not surprisingly, levels of asthma, a disease associated with air pollution-induced inflammation (Wendt et al., 2014; Evans et al., 2014; MacIntyre et al., 2013; Gonzalez-Barcala et al., 2013), are substantially higher in children with ASD, consistent with common inflammatory mechanisms in lung and brain. In a nationally representative sample of 77,951 children, asthma was 35% more common in those with ASD after controlling for age, gender, body mass index, race, brain injury, secondhand smoke and socioeconomic status (Kotey et al., 2014); further the prevalence of both ASD and asthma has been increasing (Becker, 2007; Becker and Schultz, 2010). Potential mechanistic links may also result from alterations in glutamate.

    • Developmental exposure to paracetamol causes biochemical alterations in medulla oblongata

      2015, Environmental Toxicology and Pharmacology
      Citation Excerpt :

      Although the drug can easily cross the placenta and potentially affect foetal development, most of the clinical data does not confirm the relationship between exposure to paracetamol in the early stage of pregnancy and the occurrence of an increased risk of birth defects (Rebordosa et al., 2008a,b; Scialli et al., 2010a,b). Nevertheless some investigators have assumed that prenatal and early life-threatening intake of paracetamol may induce abnormalities in the immune system, with symptoms such as wheezing and asthma (Amberbir et al., 2014; Beasley et al., 2008; Becker and Schultz, 2010; Henderson and Shaheen, 2013; Tiegs et al., 2014). In addition, recent studies have shown that the drug can affect also development of the central nervous system (CNS) and presumably is responsible for some behavioural disturbances in adulthood (Blaser and Allan, 2014; Liew et al., 2014).

    View all citing articles on Scopus
    View full text